Boston Scientific’s first quarter saw a strong positive market reaction, underpinned by solid organic sales growth and improved operating margins. Management...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...
Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2026, with sales up 11.6% year on year to $5.20 billion. O...
Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investo...
Medical device company Boston Scientific (NYSE:BSX) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 11.6% year on year to...
Boston Scientific Corp. (NYSE:BSX) shares are in the spotlight on Tuesday after Stifel maintained a Buy rating and lowered its price target on the stock.
Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday before market hours. Here’s what you need to know. Boston Scien...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
As of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (NYSE:BSX) is moving steadily toward the finalization of its $14.9 billion acquisition of Penumbra, Inc. (NYSE:PEN), a deal that represents the company's largest M&A move in
